MurrayBrentSteinMDMPH

Psychiatry • La Jolla, CA

Psychopharmacology

Distinguished Professor of Psychiatry and Public Health and at the University of California San Diego (UCSD)

Join to view full profile

Dr. Stein is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Stein's full profile

Already have an account?

Office
9500 Gilman Drive
La Jolla, CA 92093
Phone+1 858-534-6451

Summary

Dr. Murray Stein is a psychiatrist in La Jolla, CA and is affiliated with VA San Diego Healthcare System and UC San Diego Health. He received his medical degree from University of Manitoba and has been in practice 35 years. He specializes in psychopharmacology and is experienced in anxiety and traumatic stress disorders.

Education & Training

National Institutes of Health Clinical CenterResidency, Psychiatry, 1989 - 1990
National Institutes of Health Clinical CenterResidency, Psychiatry, 1986 - 1988
University of ManitobaClass of 1983

Certifications & Licensure

CA State Medical License 1994 - 2026
MD State Medical License 1986 - 1995
American Board of Psychiatry and Neurology Psychiatry

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2002-2014
Top Doctors:San Diego Area Castle Connolly, 2013
Top Doctors:Southern California Castle Connolly, 2012
Women's Health Castle Connolly, 2008
Join now to see all

Clinical Trials

Experimental Medication For the Treatment of Generalized Anxiety Disorder Start of enrollment: 2004 Nov 01
Completed
Phase 3
A Long-Term Study Continuing on From Study 04-001-01 of an Experimental Medication in Adults With Anxiety Disorder Start of enrollment: 2005 Mar 01
Completed
Phase 3
Efficacy and Tolerability of Atomoxetine (Strattera) in Adult Patients With Generalized Social Anxiety Disorder Start of enrollment: 2005 Nov 01
Completed
Phase 2, Phase 3
Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder Start of enrollment: 2006 Mar 01
Completed
Phase 4
Primary Care Intervention Strategy for Anxiety Disorders Start of enrollment: 2006 Jun 01
Completed
Phase 4
PharmacofMRI (Functional Magnetic Resonance Imaging) of Anxiolytic Medications (Alprazolam) Start of enrollment: 2008 Jan 01
Completed
Phase 4
Trial of Hydrocortisone for Post-Traumatic Stress Disorder (PTSD) Start of enrollment: 2009 Aug 01
Withdrawn
Phase 4
PharmacofMRI of Anxiolytic Medications (Pregabalin) Start of enrollment: 2008 Jun 01
Completed
Phase 4
Neural Functioning Underlying Anxiety and Its Treatment (The INSULA Study) Start of enrollment: 2007 Oct 01
Completed
Not Applicable
Post-Deployment Afghanistan/Iraq Trauma Related Inventory of Traits (PATRIOT): Phase 1 (Feasibility Study) Start of enrollment: 2011 Sep 01
Completed
Imaging Outcomes of Cognitive Behavioral Therapy (CBT) for Battered Women With Posttraumatic Stress Disorder Start of enrollment: 2008 Jan 01
Completed
Not Applicable
PROlonGed ExpoSure Sertraline Start of enrollment: 2011 Nov 01
Completed
Phase 4
Genomics of Posttraumatic Stress Disorder in Veterans Start of enrollment: 2013 Dec 01
Active, not recruiting
Negative-Positive Valence Domains in Anxiety and Depression Start of enrollment: 2013 Sep 01
Completed
Join now to see all

Publications & Presentations

PubMed

60 citations
Posttraumatic Stress Disorder and Cardiovascular Disease: State of the Science, Knowledge Gaps, and Research Opportunities
Christopher J. O'Donnell, Lisa Schwartz Longacre, Beth E. Cohen, Zahi A. Fayad, Charles F. Gillespie
JAMA Cardiology. 2021-10-01
256 citations
Developing an optimal short‐form of the PTSD Checklist for DSM‐5 (PCL‐5)
Kelly L. Zuromski, Berk Ustun, Irving Hwang, Terence M. Keane, Brian P. Marx
Depression and Anxiety. 2019-09-01
7872 citations
Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis...
Theo Vos, Amanuel Alemu Abajobir, Kalkidan Hassen Abate, Cristiana Abbafati, Kaja Abbas
Lancet. 2017-09-16

Journal Articles

Precision Psychiatry—Yes, but Precisely What?—Reply
Jordan W Smoller, Murray B Stein, JAMA
Predeployment Predictors of Psychiatric Disorder‐Symptoms and Interpersonal Violence During Combat Deployment
David M Benedek, Matthew K Nock, Murray B Stein, Robert J Ursano, Depression and Anxiety
The Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS): Progress Toward Understanding Suicide Among Soldiers
Murray B Stein, Robert J Ursano, Nature
Associations of Time-Related Deployment Variables with Risk of Suicide Attempt Among Soldiers
Gary H Wynn, Robert J Ursano, Murray B Stein, JAMA
Review Interoception and Mental Health: A Roadmap
Richard D Lane, Oliver G Cameron, Murray B Stein, Martin P Paulus, Jamie D Feusner, Charles B Nemeroff, ScienceDirect
Join now to see all

Other

American Psychiatric Association Publishing
Murray Stein, MD, National Institutes of Health
https://www.doximity.com/articles/faf4fa8f-7173-4c07-913f-aff08f7c8714
UpToDate, Wolters Kluwer Health - 2013-02-27
American Psychiatric Association Publishing
Murray Stein, MD, PubMed
https://www.doximity.com/articles/faf4fa8f-7173-4c07-913f-aff08f7c8714
UpToDate, Wolters Kluwer Health - 2011-07-11

Press Mentions

Bionomics Reports Promising Full Results Analysis from PREVAIL Phase 2 Study of BNC210 Social Anxiety Disorder (SAD)March 9th, 2023
Polygenic Risk Scores and Genetics in PsychiatryNovember 1st, 2022
Bionomics to Host KOL Webinar on BNC210 and Social Anxiety DisorderSeptember 21st, 2022
Join now to see all

Grant Support

Modifiable Risk And Protective Factors For Suicidal Behaviors In The US ArmyNational Institute Of Mental Health2010–2011
Neural Substrates Of Anticipation And Interoception In Anxiety DisordersNational Institute Of Mental Health2007–2011
Improving Outcomes And Understanding Response Heterogeneity In Anxiety DisordersNational Institute Of Mental Health2007–2011
Improving Outcomes In Pharmacotherapy Of Social PhobiaNational Institute Of Mental Health2005–2009
Calm: Improving Primary Care Anxiety OutcomesNational Institute Of Mental Health2005–2009
Pharmacological FMRI To Identify New Anxiolytics: A Human BioassayNational Institute Of Mental Health2007–2008
Pharmacofmri To Identify New Anxiolytics: A Human BioassayNational Institute Of Mental Health2006
Neural Substrates Of Decision-Making In AnxietyNational Institute Of Mental Health2003–2006
Improving Patient Outcomes In Anxiety DisordersNational Institute Of Mental Health2001–2005
Genetic Polymorphism And Human BehaviorNational Center For Research Resources1998–2005
Paroxetine Treatment And Social Phobia: A PET StudyNational Center For Research Resources2004
Preventing Psychiatric Sequelae Of Traumatic InjuryNational Institute Of Mental Health2001–2003
Effect Of Tryptophan Free Drink On Social Phobic PatientNational Center For Research Resources2000–2002
Improving Care For Panic Disorder In Primary CareNational Institute Of Mental Health1999–2002
Serotonergic Functioning In Social PhobiaNational Center For Research Resources1999
Pregabalin In Social PhobiaNational Center For Research Resources1999
Neurobiology Of Severe Psychological Trauma In WomenNational Center For Research Resources1999
Central Adrenergic Functioning In Social Phobia And ShynessNational Center For Research Resources1999
Assessment Of Panic &Other Anxiety Disorders In Primary CareNational Center For Research Resources1999
Lifetime Traumatic Events StudyNational Center For Research Resources1997–1999
Specificity Of Noradrenergic Dysfunction In Postraumatic Stress DisorderNational Center For Research Resources1998